Teleflex Stock News

Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.

Endoscopy Equipment Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size That Will Help Your Business Grow. Northbrook, IL -- ( SBWIRE ) -- 02/24/2022 -- This report aims to provide detailed insights into the global endoscopy equipment market . It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market. Expected Revenue Growth: The global endoscopy equipment market is projected to reach USD 39.3 billion by 2026 from USD 27.3 billion in 2021, at a CAGR of 7.5%. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=689 Key Factors Driving Market Growth: The key factors driving the growth of endoscopy equipment market include favorable government initiatives, rising number of hospitals and growing hospital investments in endoscopy facilities, technological advancements, and rising prevalence of diseases that require endoscopy.

Teleflex Incorporated (NYSE: TFX ) reported Q4 FY21 revenues of $761.9 million , up 7.1% Y/Y, up 7.9% on a constant currency basis, beating the consensus of $748.63 million. The revenue growth was attributable to higher sales from Anesthesia and … Full story available on Benzinga.com

Teleflex Inc. (TFX) CEO Liam Kelly on Q4 2021 Results - Earnings Call Transcript

Teleflex (TFX) declares $0.34/share quarterly dividend, in line with previous.Forward yield 0.42%Payable March 15; for shareholders of record March 7; ex-div March 4.See TFX…

Teleflex press release (TFX): Q4 Non-GAAP EPS of $3.60 beats by $0.07.Revenue of $761.91M (+7.1% Y/Y) beats by $12.31M.For FY2022, the company expects GAAP revenue growth of 2.3%…

Teleflex (TFX) delivered earnings and revenue surprises of 1.98% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Las Vegas, USA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Spirometers Market to Grow at a Significant CAGR of 9.30% by 2026, Examines DelveInsight The demand for Spirometers is primarily attributed to the global prevalence of respiratory disorders like asthma, COPD, cystic fibrosis, the growing aging population, and technological progress. All these factors will directly lead to a surge in the Spirometers market. DelveInsight''s Spirometers Market Insights and Forecast report provides the current and forecast Spirometers Market, upcoming innovation in the devices, individual market shares, challenges, drivers, and barriers, market trends, and key competitors in the Spirometers Market. Some of the essential factors from the Spirometers Market report: As per DelveInsight analysis, in terms of revenue share, North America is predicted to register the fastest growth and occupy the largest share in the Spirometers market. Key Spirometers companies proactively developing novel devices include names such as Hill Rom, Inc., Teleflex Incorporated, Vyaire Medical Inc., Fukuda Sangyo Co., Ltd., Chest M.I., Inc., Midmark Corporation, Futuremed USA, COSMED, MGC Diagnostics Corporation, NDD Medical Technologies, Schiller AG, MIR, Sibelmed, Smiths Medical PLC, Vitalograph, Jones Medical Instrument Company, Contec Medical Systems Co., Ltd., Medikro Oy, Clarity Medical, KoKo PFT and others.

Teleflex (NYSE:TFX) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is $3.53 (+8.6% Y/Y) and the consensus…

Teleflex Incorporated with ticker code (TFX) now have 9 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 455 and 325 and has a mean target at 408.56. Given that the stocks previous close was at 317.99 this would imply there is a potential upside of 28.5%. The day 50 moving average is 321.25 while the 200 day moving average is 363.63. The company has a market cap of $14,793m. Company Website: https://www.teleflex.com [stock_market_widget type="chart" template="basic" color="green" assets=TFX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $19,006m based on the market concensus. Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

WAYNE, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 24, 2022.

WAYNE, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide an operational

Dublin, Jan. 31, 2022 (GLOBE NEWSWIRE) -- The "Urinary Incontinence Market by Product, Incontinence Type, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com''s offering. The global urinary incontinence market was valued at $10,124.33 million in 2020, and is projected to reach $19,341.15 million by 2030, registering a CAGR of 6.8% from 2021 to 2030. The involuntary flow of urine due to a loss of bladder control is known as urinary incontinence. Urinary incontinence devices aid in collecting and holding urine; such devices help in managing urinary incontinence effectively. People undergoing urinary incontinence suffer from urine leakage that cannot be controlled. Patients suffering from severe urinary incontinence are recommended surgical treatment that incorporates devices such as urinary catheter, vaginal slings, electrical stimulation devices, and artificial urinary sphincters. Among the aforementioned incontinent devices, the most evidently used devices include indwelling catheters, external collecting systems, urine drainage bags, and catheters for intermittent catheterization (IC).